TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, ...
PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage ...
Researchers have pinpointed the precise pathway in the brain that suppresses pain in times of threatening situations. Subscribe to our newsletter for the latest sci-tech news updates. The study in ...
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-1 pivotal Phase 3 clinical ...
Combination analgesic products have been the mainstay of the treatment of moderate to severe dental pain for many years. Formulations containing an opioid analgesic, such as oxycodone, and a nonopioid ...
Clinical trials of a novel non-opioid analgesic have found it to be effective in reducing acute postoperative pain, opening the door to a new way of managing short-term pain that avoids the pitfalls ...
Codeine sulfate 15mg, 30mg, 60mg; tabs. Codeine sulfate is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of ...
The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out for its potency, but above all, in comparison with opioids, for its safety," ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback